Adalimumab Effective in Children and Adolescents With Severe Psoriasis Adalimumab Effective in Children and Adolescents With Severe Psoriasis
Adalimumab offers benefits over methotrexate in children and adolescents with severe chronic plaque psoriasis, according to a phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

JIA Uveitis Control Improved With Adalimumab + MTX JIA Uveitis Control Improved With Adalimumab + MTX
Adding adalimumab to MTX for treatment-resistant uveitis was associated with juvenile idiopathic arthritis improved disease control and enabled many patients to reduce or stop topical glucocorticoids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

AbbVie profit beats on Humira demand; cheers Trump tax plan
(Reuters) - AbbVie Inc reported a bigger-than-expected quarterly profit, lifted by demand for its flagship drug, Humira, and called President Donald Trump's tax plan "encouraging". (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Clinical trial discovers a new way to prevent children with arthritis and eye disease losing their sight
This study demonstrates the benefit of adalimumab in children with uveitis. This is the first randomised trial of its kind worldwide and the results will have a major impact in children with uveitis all around the world."Finding the best way of caring for children with arthritis and uveitisProfessor Beresford from University of Liverpool and Alder Hey Children’s NHS Foundation Trust said: "This landmark trial has demonstrated the commitment and leadership of colleagues across the UK in working closely with patients and parents in tackling a key priority of finding the very best way of caring for children with arthrit...
Source: Arthritis Research UK - April 26, 2017 Category: Rheumatology Source Type: news

What Causes Uveitis?
Discussion Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and > 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increas...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2017 Category: Drugs & Pharmacology Source Type: news

Fingernail Psoriasis Data Added to Humira Prescribing Info Fingernail Psoriasis Data Added to Humira Prescribing Info
The FDA has approved the addition of moderate to severe fingernail psoriasis data to the Humira prescribing information for those with moderate to severe chronic plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 30, 2017 Category: Dermatology Tags: Dermatology News Alert Source Type: news

U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail ps... Biopharmaceuticals, FDA AbbVie, HUMIRA, adalimumab, Fingernail Psoriasis, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2017 Category: Pharmaceuticals Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hi...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

AS: TNF Inhibitors Differ in Uveitis Risk (CME/CE)
(MedPage Today) -- Adalimumab and infliximab have lowest risk (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 18, 2017 Category: Geriatrics Source Type: news

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira ® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA ® in the Treatment of Moderate to Severe Plaque Psoriasis (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 3, 2017 Category: Pharmaceuticals Source Type: news

Infliximab vs. Adalimumab in Crohn's Disease Infliximab vs. Adalimumab in Crohn's Disease
Do the anti-TNF agents infliximab and adalimumab have comparable response characteristics? Are concomitant immunomodulators necessary for optimal response?Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 28, 2017 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news

Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. However, the median drug-price increase held steady compared to last year at 8.9% – far exceeding the U.S. inflation rate of 2%. Price increases held below 10% can still drive up total drug spending by hundreds of millions of dollars, according to the Wall Street Journal. AbbVie (NYSE:ABBV) raised the lis...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Healthcare Reform Pharma Pharmaceuticals Wall Street Beat AbbVie Allergan Inc. Johnson & Johnson Marathon Pharmaceuticals Merck Novo Nordisk Source Type: news

Remicade vs. Humira
Title: Remicade vs. HumiraCategory: MedicationsCreated: 2/27/2017 12:00:00 AMLast Editorial Review: 2/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 27, 2017 Category: Drugs & Pharmacology Source Type: news